{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.2","upperLimit":"50.5","value":"35.4"},{"groupId":"OG001","lowerLimit":"19.5","upperLimit":"48.0","value":"32.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"description":"MaHR is defined as percentage of participants with CHR or NEL. Response criteria for CHR is reported as WBC≤institutional upper limit of normal, ANC≥1000/mm\\^3, platelets ≥100,000/mm\\^3, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \\<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \\<5%, no extramedullary involvement; Response criteria for NEL is reported as WBC≤ institutional upper limit of normal, no blasts or promyelocytes in peripheral blood, BM blasts ≤5%, \\<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \\<5%, no extramedullary involvement, at least 1 of the following: (i) 20,000/mm\\^3 ≤platelets\\<100,000/mm\\^3; (ii) 500/mm\\^3≤ANC\\<1000/mm\\^3.","dispersionType":"95% Confidence Interval","groups":[{"description":"BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG000","title":"Cohort E: BP-CML/Ph+ ALL R-I"},{"description":"BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG001","title":"Cohort F: BP-CML or Ph+ ALL With T315I Mutation"}],"paramType":"NUMBER","populationDescription":"Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts E and F only.","reportingStatus":"POSTED","timeFrame":"Up to 6 months after initiation of study treatment","title":"Percentage of BP-CML/Ph+ ALL Participants With MaHR","type":"PRIMARY","unitOfMeasure":"percentage of participants"}